Search

Your search keyword '"Nieboer, Peter"' showing total 129 results
Start Over Author "Nieboer, Peter"
129 results on '"Nieboer, Peter"'

1. 70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study

Author

Verreck, Eline E. F., Kuijer, Anne, van Steenhoven, Julia E. C., Volders, José H., van der Velden, Annette W. G., Siesling, Sabine, Timmer-Bonte, Anja N. H., Smilde, Tineke J., Imholz, Alex L. T., Blanken-Peeters, Charlotte F. J. M., de Valk, Bart, Vrijaldenhoven, Suzan, Lastdrager, Willem B., Haringhuizen, Annebeth W., Hunting, Jarmo C. B., Hovenga, Sjoerd, Nieboer, Peter, Zuetenhorst, Hanneke M., Tetteroo, Geert W. M., Smorenburg, Carolien H., van Maaren, Marissa C., and van Dalen, Thijs

Published
2024
Full Text
View/download PDF

2. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

Author

Knikman, Jonathan E., Zhai, Qinglian, Lunenburg, Carin A. T. C., Henricks, Linda M., Böhringer, Stefan, van der Lee, Maaike, de Man, Femke M., Offer, Steven M., Shrestha, Shikshya, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L. T., Jeurissen, Frank J. F., Portielje, Johanna E. A., Jansen, Rob L. H., Hamberg, Paul, Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H. W., Mandigers, Caroline M. P. W., van Schaik, Ron H. N., Gelderblom, Hans, Mathijssen, Ron H. J., Schellens, Jan H. M., Cats, Annemieke, Guchelaar, Henk-Jan, and Swen, Jesse J.

Published
2024
Full Text
View/download PDF

3. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group

Author

Vincent, Jeroen, Wegdam, Johannes A., Haberkorn, Brigitte C.M., van der Harst, Erwin, Hendriks, Mathijs P., Schreurs, W.H. Hermien, Cense, Huib A., Rietbroek, Ron C., de Gier, Marie-José, van Breugel, Edwin A., de Vos, Aad I., Brosens, Rebecca P.M., Doornebosch, P.G., de Jongh, Felix E., Vles, Wouter J., den Boer, Marien O., Leijtens, Jeroen W.A., Gelderblom, A.J. Hans, Peeters, Koen C.M.J., Kuenen, Bart C., Pultrum, Bareld B., van Dodewaard-de Jong, Joyce M., Consten, Esther C.J., van de Wouw, A.J. Yes, Konsten, J.L.M., Hoekstra, R., Lutke Holzik, Martijn F., Vos, Allert H., van Hoogstraten, M.J., Schlesinger, Nis H., Creemers, Geert-Jan, de Hingh, Ignace H.J.T., Kjær, Monica L., Petersen, Lone N., Seiersen, Michael, Altaf, Rahim, van Cruijsen, Hester, Hess, Daniël A., van Leeuwen-Snoeks, Lobke L., Pronk, Apollo, Baeten, Coen I.M., van der Deure, Wendy M., Bosscha, Koop, Schut, Heidi, Leclercq, W.K.G., Simkens, L.H.J., Reijnders, Koen, van Arkel, Kees, van Grevenstein, W.M.U. Helma, van de Ven, Anthony W.H., Vuylsteke, Ronald J.C.L.M., Kuijer, Philomeen, Bakker, Sandra D., Goei, Hauwy, Helgason, Helgi H., van Acker, Gijs J.D., Temizkan, Mehmet, van Tilburg, Marc W.A., Gerhards, Michael F., Kerver, E.D., Gootjes, Elske, Nieboer, Peter, Bleeker, Wim A., Bleeker, G.R., van der Kruijssen, D.E.W., Elias, S.G., van de Ven, P.M., van Rooijen, K.L., Lam-Boer, J.’t, Mol, L., Punt, C.J.A., Sommeijer, D.W., Tanis, P.J., Nielsen, J.D., Yilmaz, M.K., van Riel, J.M.G.H., Wasowiz-Kemps, D.K., Loosveld, O.J.L., van der Schelling, G.P., de Groot, J.W.B., van Westreenen, H.L., Jakobsen, H.L., Fromm, A.L., Hamberg, P., Verseveld, M., Jaensch, C., Liposits, G.I., van Duijvendijk, P., Oulad Hadj, J., van der Hoeven, J.A.B., Trajkovic, M., de Wilt, J.H.W., and Koopman, M.

Published
2024
Full Text
View/download PDF

4. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group

Author

van der Kruijssen, D.E.W., primary, Elias, S.G., additional, van de Ven, P.M., additional, van Rooijen, K.L., additional, Lam-Boer, J. ’t, additional, Mol, L., additional, Punt, C.J.A., additional, Sommeijer, D.W., additional, Tanis, P.J., additional, Nielsen, J.D., additional, Yilmaz, M.K., additional, Van Riel, J.M.G.H., additional, Wasowiz-Kemps, D.K., additional, Loosveld, O.J.L., additional, van der Schelling, G.P., additional, de Groot, J.W.B., additional, van Westreenen, H.L., additional, Jakobsen, H.L., additional, Fromm, A.L., additional, Hamberg, P., additional, Verseveld, M., additional, Jaensch, C., additional, Liposits, G.I., additional, van Duijvendijk, P., additional, Hadj, J. Oulad, additional, van der Hoeven, J.A.B., additional, Trajkovic, M., additional, de Wilt, J.H.W., additional, Koopman, M., additional, Vincent, Jeroen, additional, Wegdam, Johannes A., additional, Haberkorn, Brigitte C.M., additional, van der Harst, Erwin, additional, Hendriks, Mathijs P., additional, Schreurs, W.H. (Hermien), additional, Cense, Huib A., additional, Rietbroek, Ron C., additional, Gier, Marie-José de, additional, de Widt-Levert, Louise M., additional, van Breugel, Edwin A., additional, de Vos, Aad I., additional, Brosens, Rebecca P.M., additional, Doornebosch, P.G., additional, de Jongh, Felix E., additional, Vles, Wouter J., additional, den Boer, Marien O., additional, Leijtens, Jeroen W.A., additional, Gelderblom, A.J. (Hans), additional, Peeters, Koen C.M.J., additional, Kuenen, Bart C., additional, Pultrum, Bareld B., additional, van Dodewaard-de Jong, Joyce M., additional, Consten, Esther C.J., additional, van de Wouw, A.J. (Yes), additional, Konsten, J.L.M., additional, Hoekstra, R., additional, Lutke Holzik, Martijn F., additional, Vos, Allert H., additional, van Hoogstraten, M.J., additional, Schlesinger, Nis H., additional, Creemers, Geert-Jan, additional, de Hingh, Ignace H.J.T., additional, Kjær, Monica L., additional, Petersen, Lone N., additional, Seiersen, Michael, additional, Altaf, Rahim, additional, van Cruijsen, Hester, additional, HessL, Daniël A., additional, van Leeuwen-Snoeks, obke L., additional, Pronk, Apollo, additional, Baeten, Coen I.M., additional, van der Deure, Wendy M., additional, Bosscha, Koop, additional, Schut, Heidi, additional, Leclercq, W.K.G., additional, Simkens, L.H.J., additional, Reijnders, Koen, additional, van Arkel, Kees, additional, van Grevenstein, W.M.U. (Helma), additional, van de Ven, Anthony W.H., additional, Vuylsteke, Ronald J.C.L.M., additional, Kuijer, Philomeen, additional, Bakker, Sandra D., additional, Goei, Hauwy, additional, Helgason, Helgi H., additional, van Acker, Gijs J.D., additional, Temizkan, Mehmet, additional, van Tilburg, Marc W.A., additional, Gerhards, Michael F., additional, Kerver, E.D., additional, Gootjes, Elske, additional, Nieboer, Peter, additional, Bleeker, Wim A., additional, and Vink, G.R., additional

Published
2024
Full Text
View/download PDF

5. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

Author

MS Medische Oncologie, Cancer, Knikman, Jonathan E., Zhai, Qinglian, Lunenburg, Carin A.T.C., Henricks, Linda M., Böhringer, Stefan, van der Lee, Maaike, de Man, Femke M., Offer, Steven M., Shrestha, Shikshya, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., van Schaik, Ron H.N., Gelderblom, Hans, Mathijssen, Ron H.J., Schellens, Jan H.M., Cats, Annemieke, Guchelaar, Henk Jan, Swen, Jesse J., MS Medische Oncologie, Cancer, Knikman, Jonathan E., Zhai, Qinglian, Lunenburg, Carin A.T.C., Henricks, Linda M., Böhringer, Stefan, van der Lee, Maaike, de Man, Femke M., Offer, Steven M., Shrestha, Shikshya, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., van Schaik, Ron H.N., Gelderblom, Hans, Mathijssen, Ron H.J., Schellens, Jan H.M., Cats, Annemieke, Guchelaar, Henk Jan, and Swen, Jesse J.

Published
2024

8. Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis.

Author

Knikman, Jonathan E., Wilting, Tycho A., Lopez-Yurda, Marta, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Nieboer, Peter, Droogendijk, Helga J., Creemers, Geert-Jan, Mandigers, Caroline M.P.W., Imholz, Alexander L.T., Mathijssen, Ron H.J., Portielje, Johanneke E.A., Valkenburg-van Iersel, Liselot, Vulink, Annelie, van der Poel, Marlene H.W., Baars, Arnold, Swen, Jesse J., and Gelderblom, Hans

Published
2023
Full Text
View/download PDF

9. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Author

Simkens, Lieke H J, van Tinteren, Harm, May, Anne, ten Tije, Albert J, Creemers, Geert-Jan M, Loosveld, Olaf J L, de Jongh, Felix E, Erdkamp, Frans L G, Erjavec, Zoran, van der Torren, Adelheid M E, Tol, Jolien, Braun, Hans J J, Nieboer, Peter, van der Hoeven, Jacobus J M, Haasjes, Janny G, Jansen, Rob L H, Wals, Jaap, Cats, Annemieke, Derleyn, Veerle A, Honkoop, Aafke H, Mol, Linda, Punt, Cornelis J A, and Koopman, Miriam

Published
2015
Full Text
View/download PDF

11. Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial

Author

Boekhout, Annelies H., Gietema, Jourik A., Milojkovic Kerklaan, Bojana, van Werkhoven, Erik D., Altena, Renske, Honkoop, Aafke, Los, Maartje, Smit, Willem M., Nieboer, Peter, Smorenburg, Carolien H., Mandigers, Caroline M. P. W., van der Wouw, Agnes J., Kessels, Lonneke, van der Velden, Annette W. G., Ottevanger, Petronella B., Smilde, Tineke, de Boer, Jaap, van Veldhuisen, Dirk J., Kema, Ido P., de Vries, Elisabeth G. E., and Schellens, Jan H. M.

Published
2016
Full Text
View/download PDF

12. Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer

Author

Smit, Karel C., Derksen, Jeroen W.G., Beets, Geerard L.O., Belt, Eric J.Th, Berbée, Maaike, Coene, Peter Paul L.O., Van Cruijsen, Hester, Davidis, Marjan A., Dekker, Jan Willem T., Van Dodewaard-De Jong, Joyce M., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, De Hingh, Ignace H.J.T., Ijzermans, Jan N.M., Janssen, Johan J.B., Konsten, Joop L.M., Los, Maartje, Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Pruijt, Hans J.F.M., Van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., Van Der Velden, Arjan Schouten, Schrauwen, Ruud W.M., Sie, Mark P.S., Sommeijer, Dirkje W., Sonneveld, Dirk J.A., Stockmann, Hein B.A.C., Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-Van Iersel, Liselot, Van Der Velden, Ankie M.T., Vles, Wouter J., Van Voorthuizen, Theo, Wegdam, Johannes A., De Wilt, Johannes H.W., Koopman, Miriam, May, Anne M., Smit, Karel C., Derksen, Jeroen W.G., Beets, Geerard L.O., Belt, Eric J.Th, Berbée, Maaike, Coene, Peter Paul L.O., Van Cruijsen, Hester, Davidis, Marjan A., Dekker, Jan Willem T., Van Dodewaard-De Jong, Joyce M., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, De Hingh, Ignace H.J.T., Ijzermans, Jan N.M., Janssen, Johan J.B., Konsten, Joop L.M., Los, Maartje, Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Pruijt, Hans J.F.M., Van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., Van Der Velden, Arjan Schouten, Schrauwen, Ruud W.M., Sie, Mark P.S., Sommeijer, Dirkje W., Sonneveld, Dirk J.A., Stockmann, Hein B.A.C., Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-Van Iersel, Liselot, Van Der Velden, Ankie M.T., Vles, Wouter J., Van Voorthuizen, Theo, Wegdam, Johannes A., De Wilt, Johannes H.W., Koopman, Miriam, and May, Anne M.

Abstract

Regular physical activity (PA) is associated with improved overall survival (OS) in stage I-III colorectal cancer (CRC) patients. This association is less defined in patients with metastatic CRC (mCRC). We therefore conducted a study in mCRC patients participating in the Prospective Dutch Colorectal Cancer cohort. PA was assessed with the validated SQUASH questionnaire, filled-in within a maximum of 60 days after diagnosis of mCRC. PA was quantified by calculating Metabolic Equivalent Task (MET) hours per week. American College of Sports and Medicine (ACSM) PA guideline adherence, tertiles of moderate to vigorous PA (MVPA), and sport and leisure time MVPA (MVPA-SL) were assessed as well. Vital status was obtained from the municipal population registry. Cox proportional-hazards models were used to study the association between PA determinants and all-cause mortality adjusted for prognostic patient and treatment-related factors. In total, 293 mCRC patients (mean age 62.9±10.6 years, 67% male) were included in the analysis. Compared to low levels, moderate and high levels of MET-hours were significantly associated with longer OS (fully adjusted hazard ratios: 0.491, (95% CI 0.299-0.807, p value=0.005) and 0.485 (95% CI 0.303-0.778, p value=0.003), respectively), as were high levels of MVPA (0.476 (95% CI 0.278-0.816, p value=0.007)) and MVPA-SL (0.389 (95% CI 0.224-0.677, p value<0.001)), and adherence to ACSM PA guidelines compared to non-adherence (0.629 (95% CI 0.412-0.961, p value=0.032)). The present study provides evidence that higher PA levels at diagnosis of mCRC are associated with longer OS.

Published
2022

13. Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer

Author

Epi Kanker Team B, Cancer, MS Medische Oncologie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Smit, Karel C, Derksen, Jeroen W G, Beets, Geerard L O, Belt, Eric J Th, Berbée, Maaike, Coene, Peter Paul L O, van Cruijsen, Hester, Davidis, Marjan A, Dekker, Jan Willem T, van Dodewaard-de Jong, Joyce M, Haringhuizen, Annebeth W, Helgason, Helgi H, Hendriks, Mathijs P, Hoekstra, Ronald, de Hingh, Ignace H J T, IJzermans, Jan N M, Janssen, Johan J B, Konsten, Joop L M, Los, Maartje, Mekenkamp, Leonie J M, Nieboer, Peter, Peeters, Koen C M J, Peters, Natascha A J B, Pruijt, Hans J F M, Quarles van Ufford-Mannesse, Patricia, Rietbroek, Ron C, Schiphorst, Anandi H W, Schouten van der Velden, Arjan, Schrauwen, Ruud W M, Sie, Mark P S, Sommeijer, Dirkje W, Sonneveld, Dirk J A, Stockmann, Hein B A C, Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L R, Valkenburg-van Iersel, Liselot, van der Velden, Ankie M T, Vles, Wouter J, van Voorthuizen, Theo, Wegdam, Johannes A, de Wilt, Johannes H W, Koopman, Miriam, May, Anne M, On Behalf Of The Plcrc Study Group, Epi Kanker Team B, Cancer, MS Medische Oncologie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Smit, Karel C, Derksen, Jeroen W G, Beets, Geerard L O, Belt, Eric J Th, Berbée, Maaike, Coene, Peter Paul L O, van Cruijsen, Hester, Davidis, Marjan A, Dekker, Jan Willem T, van Dodewaard-de Jong, Joyce M, Haringhuizen, Annebeth W, Helgason, Helgi H, Hendriks, Mathijs P, Hoekstra, Ronald, de Hingh, Ignace H J T, IJzermans, Jan N M, Janssen, Johan J B, Konsten, Joop L M, Los, Maartje, Mekenkamp, Leonie J M, Nieboer, Peter, Peeters, Koen C M J, Peters, Natascha A J B, Pruijt, Hans J F M, Quarles van Ufford-Mannesse, Patricia, Rietbroek, Ron C, Schiphorst, Anandi H W, Schouten van der Velden, Arjan, Schrauwen, Ruud W M, Sie, Mark P S, Sommeijer, Dirkje W, Sonneveld, Dirk J A, Stockmann, Hein B A C, Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L R, Valkenburg-van Iersel, Liselot, van der Velden, Ankie M T, Vles, Wouter J, van Voorthuizen, Theo, Wegdam, Johannes A, de Wilt, Johannes H W, Koopman, Miriam, May, Anne M, and On Behalf Of The Plcrc Study Group

Published
2022

14. Quality of life and quality of care as experienced by patients with advanced cancer and their relatives: A multicentre observational cohort study (eQuiPe)

Author

van Roij, Janneke, primary, Raijmakers, Natasja, additional, Ham, Laurien, additional, van den Beuken-van Everdingen, Marieke, additional, van den Borne, Ben, additional, Creemers, Geert-Jan, additional, Cornelis Hunting, Jarmo, additional, Kuip, Evelien, additional, van Leeuwen, Lobke, additional, van Laarhoven, Hanneke, additional, Mandigers, Caroline, additional, Nieboer, Peter, additional, van der Velden, Lilly-Ann, additional, Zuylen, Lia van, additional, Gelissen, John, additional, Zijlstra, Myrte, additional, Brom, Linda, additional, Fransen, Heidi P., additional, and van de Poll-Franse, Lonneke, additional

Published
2022
Full Text
View/download PDF

15. Trajectories of health-related quality of life and psychological distress in patients with colorectal cancer: A population-based study

Author

Qaderi, Seyed M., primary, van der Heijden, Joost A.G., additional, Verhoeven, Rob H.A., additional, de Wilt, Johannes H.W., additional, Custers, Jose A.E., additional, Beets, Geerard L., additional, Belt, Eric J.Th., additional, Berbée, Maaike, additional, Beverdam, Frederique H., additional, Blankenburgh, Ruud, additional, Coene, Peter Paul L.O., additional, de Groot, Jan Willem B., additional, de Hingh, Ignace H.J.T., additional, de Vos, Aad I., additional, Dekker, Jan Willem T., additional, Erdkamp, Frans L.G., additional, Haringhuizen, Annebeth W., additional, Helgason, Helgi H., additional, Hendriks, Mathijs P., additional, Hoekstra, Ronald, additional, Ijzermans, Jan N.M., additional, Jansen, Jan, additional, Kloppenberg, Frank W.H., additional, Los, Maartje, additional, Meijerink, Martijn R., additional, Mekenkamp, Leonie J.M., additional, Nieboer, Peter, additional, Peeters, Koen C.M.J., additional, Peters, Natascha A.J.B., additional, Polée, Marco B., additional, Pruijt, Johannes F.M., additional, van Ufford-Mannesse, Patricia Quarles, additional, Rietbroek, Ron C., additional, Schiphorst, Anandi H.W., additional, van der Velden, Arjan Schouten, additional, Schrauwen, Ruud W.M., additional, Sie, Mark P.S., additional, Simkens, Lieke, additional, Sommeijer, Dirkje W., additional, Sonneveld, Dirk J.A., additional, Spierings, Leontine E.A., additional, Stockmann, Hein B.A.C., additional, Talsma, Koen, additional, ten Tije, Albert J., additional, Terheggen, Frederiek, additional, Tjin-A-Ton, Manuel L.R., additional, Valkenburg-van Iersel, Liselot B.J., additional, van Cruijsen, Hester, additional, Velden, Ankie M.T. van der, additional, van Dodewaard-de Jong, Joyce M., additional, van Lent, Anja U.G., additional, van Voorthuizen, Theo, additional, Vermaas, Maarten, additional, Vles, Wouter J., additional, Vogelaar, Jeroen F.J., additional, and Zimmerman, David D.E., additional

Published
2021
Full Text
View/download PDF

16. The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care

Author

Derksen, Jeroen W. G., Vink, Geraldine R., Elferink, Marloes A. G., Roodhart, Jeanine M. L., Verkooijen, Helena M., van Grevenstein, Wilhelmina M. U., Siersema, Peter D., May, Anne M., Koopman, Miriam, Beets, Geerard L., Belt, Eric J. Th., Berbée, Maaike, Beverdam, Frederique H., Blankenburgh, Ruud, Coene, Peter Paul L. O., van Cruijsen, Hester, Dekker, Jan Willem T., van Dodewaard-de Jong, Joyce M., Erdkamp, Frans L. G., de Groot, Jan Willem B., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., de Hingh, Ignace H. J. T., Hoekstra, Ronald, Ijzermans, Jan N. M., Jansen, Jan, Kloppenberg, Frank W. H., van Lent, Anja U. G., Los, Maartje, Meijerink, Martijn R., Mekenkamp, Leonie J. M., Nieboer, Peter, Peeters, Koen C. M. J., Peters, Natascha A. J. B., Polée, Marco B., Pruijt, Johannes F. M., Punt, Cornelis J. A., van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H. W., van der Velden, Arjan Schouten, Schrauwen, Ruud W. M., Sie, Mark P. S., Simkens, Lieke, Sommeijer, Dirkje W., Sonneveld, Dirk J. A., Spierings, Leontine E. A., Stockmann, Hein B. A. C., Talsma, Koen, Terheggen, Frederiek, ten Tije, Albert J., Tjin-A-Ton, Manuel L. R., Valkenburg-van Iersel, Liselot B. J., Veenstra, Renzo P., van der Velden, Ankie M. T., Vermaas, Maarten, Vles, Wouter J., Vogelaar, Jeroen F. J., van Voorthuizen, Theo, de Vos, Aad I., Wegdam, Johannes A., de Wilt, Johannes H. W., Zimmerman, David D. E., Surgery, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Epidemiologie, CCA - Cancer Treatment and quality of life, Radiology and nuclear medicine, Internal medicine, and VU University medical center

Subjects
Male, medicine.medical_specialty, Colorectal cancer, Epidemiology, Science, Population, MODELS, MEDLINE, Logistic regression, Representativeness heuristic, Article, 03 medical and health sciences, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Cancer epidemiology, Medical research, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Multidisciplinary approach, COLON, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Registries, education, Aged, Netherlands, Aged, 80 and over, education.field_of_study, Multidisciplinary, business.industry, Middle Aged, medicine.disease, Cancer registry, TRIALS, Outcomes research, 030220 oncology & carcinogenesis, Family medicine, Cohort, Medicine, Female, business, Colorectal Neoplasms
Abstract

Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, linked to the Netherlands Cancer Registry, serves as an infrastructure for scientific research collecting additional patient-reported outcomes (PRO) and biospecimens. Here we report on cohort developments and investigate to what extent PLCRC reflects the “real-world”. Clinical and demographic characteristics of PLCRC participants were compared with the general Dutch CRC population (n = 74,692, Dutch-ref). To study representativeness, standardized differences between PLCRC and Dutch-ref were calculated, and logistic regression models were evaluated on their ability to distinguish cohort participants from the Dutch-ref (AU-ROC 0.5 = preferred, implying participation independent of patient characteristics). Stratified analyses by stage and time-period (2013–2016 and 2017–Aug 2019) were performed to study the evolution towards RWD. In August 2019, 5744 patients were enrolled. Enrollment increased steeply, from 129 participants (1 hospital) in 2013 to 2136 (50 of 75 Dutch hospitals) in 2018. Low AU-ROC (0.65, 95% CI: 0.64–0.65) indicates limited ability to distinguish cohort participants from the Dutch-ref. Characteristics that remained imbalanced in the period 2017–Aug’19 compared with the Dutch-ref were age (65.0 years in PLCRC, 69.3 in the Dutch-ref) and tumor stage (40% stage-III in PLCRC, 30% in the Dutch-ref). PLCRC approaches to represent the Dutch CRC population and will ultimately meet the current demand for high-quality RWD. Efforts are ongoing to improve multidisciplinary recruitment which will further enhance PLCRC’s representativeness and its contribution to a learning healthcare system.

Published
2021

17. Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer

Author

Kroon, Lente L., Van Roij, Janneke, Korfage, Ida J., Reyners, An K. L., Van Den Beuken-van Everdingen, Marieke H. J., Den Boer, Marien O., Creemers, Geert-jan, De Graeff, Alexander, Hendiks, Mathijs P., Hunting, Jarmo C. B., De Jong, Wouter K., Kuip, Evelien J. M., Van Laarhoven, Hanneke W. M., Van Leeuwen, Lobke, Van Lindert, Anne S. R., Mandigers, Caroline M. P. W., Nieboer, Peter, Van Der Padt-Pruijsten, Annemieke, Smilde, Tineke J., Sommeijer, Dirkje W., Thijs, Martine F., Tiemessen, Marian A., Vos, Allert H., Vreugdenhil, Art, Werner, Philo T., Van Zuylen, Lia, van de Poll-Franse, Lonneke V., Raijmakers, Natasja J. H., Kroon, Lente L., Van Roij, Janneke, Korfage, Ida J., Reyners, An K. L., Van Den Beuken-van Everdingen, Marieke H. J., Den Boer, Marien O., Creemers, Geert-jan, De Graeff, Alexander, Hendiks, Mathijs P., Hunting, Jarmo C. B., De Jong, Wouter K., Kuip, Evelien J. M., Van Laarhoven, Hanneke W. M., Van Leeuwen, Lobke, Van Lindert, Anne S. R., Mandigers, Caroline M. P. W., Nieboer, Peter, Van Der Padt-Pruijsten, Annemieke, Smilde, Tineke J., Sommeijer, Dirkje W., Thijs, Martine F., Tiemessen, Marian A., Vos, Allert H., Vreugdenhil, Art, Werner, Philo T., Van Zuylen, Lia, van de Poll-Franse, Lonneke V., and Raijmakers, Natasja J. H.

Abstract

Purpose Advance Care Planning (ACP) is positively associated with the quality of care, but its impact on emotional functioning is ambiguous. This study investigated the association between perceptions of ACP involvement and emotional functioning in patients with advanced cancer. Methods This study analyzed baseline data of 1,001 patients of the eQuiPe study, a prospective, longitudinal, multicenter, observational study on quality of care and quality of life in patients with advanced cancer in the Netherlands. Patients with metastatic solid cancer were asked to participate between November 2017 and January 2020. Patients’ perceptions of ACP involvement were measured by three self-administered statements. Emotional functioning was measured by the EORTC-QLQ-C30. A linear multivariable regression analysis was performed while taking gender, age, migrant background, education, marital status, and symptom burden into account. Results The majority of patients (87%) reported that they were as much involved as they wanted to be in decisions about their future medical treatment and care. Most patients felt that their relatives (81%) and physicians (75%) were familiar with their preferences for future medical treatment and care. A positive association was found between patients’ perceptions of ACP involvement and their emotional functioning (b=0.162, p<0.001, 95%CI[0.095;0.229]) while controlling for relevant confounders. Conclusions Perceptions of involvement in ACP are positively associated with emotional functioning in patients with advanced cancer. Future studies are needed to further investigate the effect of ACP on emotional functioning. Trial registration number NTR6584 Date of registration: 30 June 2017 Implications for Cancer Survivors Patients’ emotional functioning might improve from routine discussions regarding goals of future care. Therefore, integration of ACP into palliative might be promisi

Published
2021

19. Work Ability in Patients With Stage I to IV Colon Cancer: Results of the Dutch Prospective Colorectal Cancer Cohort

Author

Franken, Mira D., Vink, Geraldine, van Grevenstein, Wilhelmina M.U., Verkooijen, Helena M., Punt, Cornelis J.A., Koopman, Miriam, May, Anne M., Beets, Geerard L., Belt, Eric J.Th., Berbée, Maaike, Beverdam, Frederique H., Blankenburgh, Ruud, Coene, Peter Paul L.O., de Groot, Jan Willem B., de Hingh, Ignace H.J.T., de Vos, Aad I., de Wilt, Johannes H.W., Dekker, Jan Willem T., Erdkamp, Frans L.G., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, Ijzermans, Jan N.M., Jansen, Jan, Kloppenberg, Frank W.H., Los, Maartje, Meijerink, Martijn R., Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Pruijt, Johannes F.M., van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., Sie, Mark P.S., Simkens, Lieke H.J., Sommeijer, Dirkje W., Spierings, Leontine E.A., Stockmann, Hein B.A.C., ten Tije, Albert J., Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-van Iersel, Liselot B.J., van Cruijsen, Hester, van der Velden, Ankie M.T., van Dodewaard-de Jong, Joyce M., van Lent, Anja U.G., Voorthuizen, Theo van, Vermaas, Maarten, Vles, Wouter J., Vogelaar, Jeroen F.J., and Zimmerman, David D.E.

Published
2023
Full Text
View/download PDF

20. Prospective cohort study of patients with advanced cancer and their relatives on the experienced quality of care and life (eQuiPe study): A study protocol

Author

van Roij, Janneke, Zijlstra, Myrte, Ham, Laurien, Brom, Linda, Fransen, Heidi, Vreugdenhil, Art, Raijmakers, Natasja, van de Poll-Franse, Lonneke, Youssef-Elsoud, Maggy, Creemers, Geert-Jan, van den Borne, Ben, de Jong, Wouter, Baars, Arnold, van den Beuken - van Everdingen, Marieke, Kuip, Evelien, Bunnik, René, Hendriks, Mathijs, Mandigers, Caroline, van Basten, Jean-Paul, van Kampen - van den Boogaart, Vivian, Werner, Philo, van Zuylen, Lia, de Graeff, Alexander, van Lindert, Anne, Soesan, Marcel, Hunting, Jarmo, Smals, Arno, van de Winkel, Linda, Stege, Gerben, Verhaert, Liese, Peters, Natascha, Pepels, Manon, Smilde, Tineke, Nieboer, Peter, de Hosson, Sander, den Boer, Marien, Pitz, Cordula, Heyne, Rick, Tjin-A-Ton, Manuel, van der Padt - Pruijsten, Annemieke, van den Berg, Paul, Krouwels, Frans, van Leeuwen-Snoeks, Lobke, van der Meer, Femke, Vos, Allert, Veldhuis, Gerrit Jan, Poppema, Boelo, Thijs-Visser, Martine, Heller-Baan, Roxane, van Laren, Marjolein, van den Brink, Karen Maassen, Douma, Gea, Kloover, Jeroen, Sommeijer, Dirkje, Pronk, Lemke, Janssens - van Vliet, Ellen, van der Velden, Lilly-Ann, Hafkamp, Emma, Codrington, Henk, Tarasevych, Svitlana, van Bochove, Aart, de Boer, Jaap, Vink, Geraldine, Oncology, Medical and Clinical Psychology, Internal medicine, CCA - Cancer Treatment and quality of life, and VU University medical center

Subjects
Adult, Quality of life, medicine.medical_specialty, Palliative care, Population, lcsh:Special situations and conditions, Disease, Cohort Studies, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, 0302 clinical medicine, Clinical Protocols, Neoplasms, Surveys and Questionnaires, Advanced cancer, Study protocol, Humans, Medicine, Family, Longitudinal Studies, Prospective Studies, 030212 general & internal medicine, Prospective study, education, Prospective cohort study, Netherlands, Quality of Health Care, Terminal Care, education.field_of_study, business.industry, lcsh:RC952-1245, Quality of care, General Medicine, Relatives, Cancer registry, Longitudinal cohort study, 030220 oncology & carcinogenesis, Family medicine, Population study, business, Cohort study
Abstract

Background Palliative care is becoming increasingly important because the number of patients with an incurable disease is growing and their survival is improving. Previous research tells us that early palliative care has the potential to improve quality of life (QoL) in patients with advanced cancer and their relatives. According to limited research on palliative care in the Netherlands, patients with advanced cancer and their relatives find current palliative care suboptimal. The aim of the eQuiPe study is to understand the experienced quality of care (QoC) and QoL of patients with advanced cancer and their relatives to further improve palliative care. Methods A prospective longitudinal observational cohort study is conducted among patients with advanced cancer and their relatives. Patients and relatives receive a questionnaire every 3 months regarding experienced QoC and QoL during the palliative trajectory. Bereaved relatives receive a final questionnaire 3 to 6 months after the patients’ death. Data from questionnaires are linked with detailed clinical data from the Netherlands Cancer Registry (NCR). By means of descriptive statistics we will examine the experienced QoC and QoL in our study population. Differences between subgroups and changes over time will be assessed while adjusting for confounding factors. Discussion This study will be the first to prospectively and longitudinally explore experienced QoC and QoL in patients with advanced cancer and their relatives simultaneously. This study will provide us with population-based information in patients with advanced cancer and their relatives including changes over time. Results from the study will inform us on how to further improve palliative care. Trial registration Trial NL6408 (NTR6584). Registered in Netherlands Trial Register on June 30, 2017.

Published
2020

21. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): Study protocol for a trial within a cohort study

Author

Schraa, S. J., Van Rooijen, K. L., Van Der Kruijssen, D. E.W., Rubio Alarcón, C., Phallen, J., Sausen, M., Simmons, J., Coupé, V. M.H., Van Grevenstein, W. M.U., Elias, S., Verkooijen, H. M., Laclé, M. M., Bosch, L. J.W., Van Den Broek, D., Meijer, G. A., Velculescu, V. E., Fijneman, R. J.A., Vink, G. R., Koopman, M., Dunker, Mich S., Lutke Holzik, Martijn F., Hoekstra, Ronald, Sommeijer, Dirkje W., Van Der Bilt, Jarmila D.W., Consten, Esther C.J., Cirkel, Geert A., Burghgraef, Thijs A., Van Der Schans, Emma M., Nieboer, Peter, Rietbroek, Ron C., Dekker, Jan Willem T., Verschoor, Arjan J., Talsma, Koen A.K., Brosens, Rebecca P.M., Helgason, Helgi H., Marinelli, Andreas W.K.S., De Hingh, Ignace H.J.T., Oldenhuis, Corina N., Jansen, Jan, Van Halteren, Henk K., Stockmann, Hein B.A.C., Beeker, Aart, Bosscha, Koop, Pruijt, Hans F.M., Spierings, Leontine E.A.M.M., Valkenburg-Van Iersel, Liselot B.J., Vles, Wouter J., De Jongh, Felix E., Van Cruijsen, Hester, Heikens, Joost T., Zimmerman, David D.E., Van Alphen, Robert J., Schiphorst, Anandi H.W., Van Leeuwen-Snoeks, Lobke L., Vogelaar, Jeroen F.J., Peters, Natascha A.J.B., Epidemiology and Data Science, APH - Methodology, CCA - Cancer Treatment and quality of life, Pathology, Internal medicine, Orthopedic Surgery and Sports Medicine, VU University medical center, Surgery, ​Robotics and image-guided minimally-invasive surgery (ROBOTICS), RS: NUTRIM - R3 - Respiratory & Age-related Health, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Medical Biology, Nephrology, and Oncology

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Neoplasm, Residual, Colorectal cancer, Cost-Benefit Analysis, COLORECTAL-CANCER, Circulating Tumor DNA, Study Protocol, 0302 clinical medicine, RESIDUAL DISEASE, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Prospective Studies, Colectomy, Netherlands, Randomized Controlled Trials as Topic, RISK, education.field_of_study, RANDOMIZED CONTROLLED-TRIAL, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Colon cancer, Oxaliplatin, Chemotherapy, Adjuvant, CELL-FREE DNA, 030220 oncology & carcinogenesis, Colonic Neoplasms, Practice Guidelines as Topic, SURVIVAL, Female, medicine.drug, Cohort study, Adult, medicine.medical_specialty, Population, TwiCs, lcsh:RC254-282, Disease-Free Survival, LEUCOVORIN, Capecitabine, 03 medical and health sciences, Internal medicine, Genetics, medicine, Biomarkers, Tumor, Humans, RECURRENCE, education, Neoplasm Staging, Intention-to-treat analysis, business.industry, Liquid Biopsy, ctDNA, Patient Acceptance of Health Care, medicine.disease, Minimal residual disease, FLUOROURACIL, Adjuvant chemotherapy, 030104 developmental biology, Quality of Life, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form adjuvant chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicative for MRD and has high predictive value for recurrent disease. The MEDOCC-CrEATE trial investigates how many stage II CC patients with detectable ctDNA after surgery will accept ACT and whether ACT reduces the risk of recurrence in these patients. Methods/design MEDOCC-CrEATE follows the ‘trial within cohorts’ (TwiCs) design. Patients with colorectal cancer (CRC) are included in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) and give informed consent for collection of clinical data, tissue and blood samples, and consent for future randomization. MEDOCC-CrEATE is a subcohort within PLCRC consisting of 1320 stage II CC patients without indication for ACT according to current guidelines, who are randomized 1:1 into an experimental and a control arm. In the experimental arm, post-surgery blood samples and tissue are analyzed for tissue-informed detection of plasma ctDNA, using the PGDx elio™ platform. Patients with detectable ctDNA will be offered ACT consisting of 8 cycles of capecitabine plus oxaliplatin while patients without detectable ctDNA and patients in the control group will standard follow-up according to guideline. The primary endpoint is the proportion of patients receiving ACT when ctDNA is detectable after resection. The main secondary outcome is 2-year recurrence rate (RR), but also includes 5-year RR, disease free survival, overall survival, time to recurrence, quality of life and cost-effectiveness. Data will be analyzed by intention to treat. Discussion The MEDOCC-CrEATE trial will provide insight into the willingness of stage II CC patients to be treated with ACT guided by ctDNA biomarker testing and whether ACT will prevent recurrences in a high-risk population. Use of the TwiCs design provides the opportunity to randomize patients before ctDNA measurement, avoiding ethical dilemmas of ctDNA status disclosure in the control group. Trial registration Netherlands Trial Register: NL6281/NTR6455. Registered 18 May 2017, https://www.trialregister.nl/trial/6281

Published
2020

29. Additional file 3 of Effects of oncological care pathways in primary and secondary care on patient, professional and health systems outcomes: a systematic review and meta-analysis

Author

Hoeve, Jolanda C. Van, Vernooij, Robin W. M., Fiander, Michelle, Nieboer, Peter, Siesling, Sabine, and Rotter, Thomas

Subjects
technology, industry, and agriculture, lipids (amino acids, peptides, and proteins)
Abstract

Additional file 3. Systematic review cancer care pathways PRISMA flow diagram.

Published
2020
Full Text
View/download PDF

31. Patients’ perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict

Author

Cancer, Pathologie Groep Van Diest, Onderzoek Beeld, Pathologie, van Steenhoven, Julia E.C., den Dekker, Bianca M., Kuijer, Anne, van Diest, Paul J., Nieboer, Peter, Zuetenhorst, Johanna M., Imholz, Alex L.Th, Siesling, Sabine, van Dalen, Thijs, Cancer, Pathologie Groep Van Diest, Onderzoek Beeld, Pathologie, van Steenhoven, Julia E.C., den Dekker, Bianca M., Kuijer, Anne, van Diest, Paul J., Nieboer, Peter, Zuetenhorst, Johanna M., Imholz, Alex L.Th, Siesling, Sabine, and van Dalen, Thijs

Published
2020

33. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer

Author

Onderzoek Medische Oncologie, Cancer, Arts-assistenten Radiotherapie, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, Epi Kanker Team A, MS Medische Oncologie, Epidemiology & Health Economics, Derksen, Jeroen W G, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, Jourdan, Marion, van der Velden, Ankie M T, Nieboer, Peter, de Jong, Robert S, Honkoop, Aafke H, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Onderzoek Medische Oncologie, Cancer, Arts-assistenten Radiotherapie, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, Epi Kanker Team A, MS Medische Oncologie, Epidemiology & Health Economics, Derksen, Jeroen W G, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, Jourdan, Marion, van der Velden, Ankie M T, Nieboer, Peter, de Jong, Robert S, Honkoop, Aafke H, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

35. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer

Author

Derksen, Jeroen W.G., primary, Kurk, Sophie A., additional, Peeters, Petra H.M., additional, Dorresteijn, Bram, additional, Jourdan, Marion, additional, Velden, Ankie M.T., additional, Nieboer, Peter, additional, Jong, Robert S., additional, Honkoop, Aafke H., additional, Punt, Cornelis J.A., additional, Koopman, Miriam, additional, and May, Anne M., additional

Published
2020
Full Text
View/download PDF

37. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, van Werkhoven, Erik, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, van Werkhoven, Erik, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, and Schellens, Jan H M

Abstract

BACKGROUND: Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe treatment-related toxicity in up to 30% of patients. Toxicity is often related to reduced activity of dihydropyrimidine dehydrogenase, the main metabolic fluoropyrimidine enzyme, primarily caused by genetic DPYD polymorphisms. In a large prospective study, it was concluded that upfront DPYD-guided dose individualisation is able to improve safety of fluoropyrimidine-based therapy. In our current analysis, we evaluated whether this strategy is cost saving.METHODS: A cost-minimisation analysis from a health-care payer perspective was performed as part of the prospective clinical trial (NCT02324452) in which patients prior to start of fluoropyrimidine-based therapy were screened for the DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A and received an initial dose reduction of 25% (c.2846A>T, c.1236G>A) or 50% (DPYD*2A, c.1679T>G). Data on treatment, toxicity, hospitalisation and other toxicity-related interventions were collected. The model compared prospective screening for these DPYD variants with no DPYD screening. One-way and probabilistic sensitivity analyses were also performed.RESULTS: Expected total costs of the screening strategy were €2599 per patient compared with €2650 for non-screening, resulting in a net cost saving of €51 per patient. Results of the probabilistic sensitivity and one-way sensitivity analysis demonstrated that the screening strategy was very likely to be cost saving or worst case cost-neutral.CONCLUSIONS: Upfront DPYD-guided dose individualisation, improving patient safety, is cost saving or cost-neutral but is not expected to yield additional costs. These results endorse implementing DPYD screening before start of fluoropyrimidine treatment as standard of care.

Published
2019

38. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, Schellens, Jan H.M., Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, and Schellens, Jan H.M.

Published
2019

39. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, van Werkhoven, Erik, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, van Werkhoven, Erik, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, and Schellens, Jan H M

Published
2019

40. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Apotheek Opleiding, UMC Utrecht, HEE, Child Health, JC onderzoeksprogramma Methodologie, MS Medische Oncologie, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, Schellens, Jan H.M., Apotheek Opleiding, UMC Utrecht, HEE, Child Health, JC onderzoeksprogramma Methodologie, MS Medische Oncologie, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, and Schellens, Jan H.M.

Published
2019

41. Additional file 2: of Effects of oncological care pathways in primary and secondary care on patient, professional, and health systems outcomes: protocol for a systematic review and meta-analysis

Author

Hoeve, Jolanda Van, Vernooij, Robin, Adegboyega Lawal, Fiander, Michelle, Nieboer, Peter, Siesling, Sabine, and Rotter, Thomas

Subjects
body regions, nervous system, fungi
Abstract

OVID MEDLINE search strategy oncology care pathways review. (PDF 23Â kb)

Published
2018
Full Text
View/download PDF

43. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Henricks, Linda M., primary, Lunenburg, Carin A.T.C., additional, de Man, Femke M., additional, Meulendijks, Didier, additional, Frederix, Geert W.J., additional, Kienhuis, Emma, additional, Creemers, Geert-Jan, additional, Baars, Arnold, additional, Dezentjé, Vincent O., additional, Imholz, Alexander L.T., additional, Jeurissen, Frank J.F., additional, Portielje, Johanna E.A., additional, Jansen, Rob L.H., additional, Hamberg, Paul, additional, ten Tije, Albert J., additional, Droogendijk, Helga J., additional, Koopman, Miriam, additional, Nieboer, Peter, additional, van de Poel, Marlène H.W., additional, Mandigers, Caroline M.P.W., additional, Rosing, Hilde, additional, Beijnen, Jos H., additional, van Werkhoven, Erik, additional, van Kuilenburg, André B.P., additional, van Schaik, Ron H.N., additional, Mathijssen, Ron H.J., additional, Swen, Jesse J., additional, Gelderblom, Hans, additional, Cats, Annemieke, additional, Guchelaar, Henk-Jan, additional, and Schellens, Jan H.M., additional

Published
2019
Full Text
View/download PDF

44. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Author

Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, and Schellens, Jan H M

Abstract

BACKGROUND: Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD), mostly caused by genetic variants in the gene encoding DPD (DPYD). We assessed the effect of prospective screening for the four most relevant DPYD variants (DPYD*2A [rs3918290, c.1905+1G>A, IVS14+1G>A], c.2846A>T [rs67376798, D949V], c.1679T>G [rs55886062, DPYD*13, I560S], and c.1236G>A [rs56038477, E412E, in haplotype B3]) on patient safety and subsequent DPYD genotype-guided dose individualisation in daily clinical care.METHODS: In this prospective, multicentre, safety analysis in 17 hospitals in the Netherlands, the study population consisted of adult patients (≥18 years) with cancer who were intended to start on a fluoropyrimidine-based anticancer therapy (capecitabine or fluorouracil as single agent or in combination with other chemotherapeutic agents or radiotherapy). Patients with all tumour types for which fluoropyrimidine-based therapy was considered in their best interest were eligible. We did prospective genotyping for DPYD*2A, c.2846A>T, c.1679T>G, and c.1236G>A. Heterozygous DPYD variant allele carriers received an initial dose reduction of 25% (c.2846A>T and c.1236G>A) or 50% (DPYD*2A and c.1679T>G), and DPYD wild-type patients were treated according to the current standard of care. The primary endpoint of the study was the frequency of severe (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 grade ≥3) overall fluoropyrimidine-related toxicity across the entire treatment duration. We compared toxicity incidence between DPYD variant allele carriers and DPYD wild-type patients on an intention-to-treat basis, and relative risks (RRs) for severe toxicity were compared between the current study and a historical cohort of DPYD variant allele carriers treated with full dose fluor

Published
2018

45. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer : a prospective safety analysis

Author

Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., Werkhoven, Erik van, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, Schellens, Jan H.M., Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., Werkhoven, Erik van, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, and Schellens, Jan H.M.

Published
2018

46. Conventional pathology versus gene signatures for assessing luminal A and B type breast cancers : Results of a prospective cohort study

Author

van Steenhoven, Julia E.C., Kuijer, Anne, van Diest, Paul J., van Gorp, Joost M., Straver, Marieke, Elias, Sjoerd G., Wesseling, Jelle, Rutgers, Emiel, Timmer-Bonte, Johanna N.H., Nieboer, Peter, Smilde, Tineke J., Imholz, Alex, Blanken, Charlotte F.J.M., Siesling, Sabine, van Dalen, Thijs, van Steenhoven, Julia E.C., Kuijer, Anne, van Diest, Paul J., van Gorp, Joost M., Straver, Marieke, Elias, Sjoerd G., Wesseling, Jelle, Rutgers, Emiel, Timmer-Bonte, Johanna N.H., Nieboer, Peter, Smilde, Tineke J., Imholz, Alex, Blanken, Charlotte F.J.M., Siesling, Sabine, and van Dalen, Thijs

Published
2018

47. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, and Schellens, Jan H M

Published
2018

48. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Author

Apotheek Opleiding, UMC Utrecht, HEE, Child Health, JC onderzoeksprogramma Methodologie, MS Medische Oncologie, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., Werkhoven, Erik van, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, Schellens, Jan H.M., Apotheek Opleiding, UMC Utrecht, HEE, Child Health, JC onderzoeksprogramma Methodologie, MS Medische Oncologie, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., Werkhoven, Erik van, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, and Schellens, Jan H.M.

Published
2018

49. Conventional pathology versus gene signatures for assessing luminal A and B type breast cancers: Results of a prospective cohort study

Author

Pathologie Groep Van Diest, Trialbureau Beeld, Cancer, Pathologie Stafondersteuning, Pathologie, Pathologie Pathologen staf, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Kanker, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, MS CGO, van Steenhoven, Julia E.C., Kuijer, Anne, van Diest, Paul J., van Gorp, Joost M., Straver, Marieke, Elias, Sjoerd G., Wesseling, Jelle, Rutgers, Emiel, Timmer-Bonte, Johanna N.H., Nieboer, Peter, Smilde, Tineke J., Imholz, Alex, Blanken, Charlotte F.J.M., Siesling, Sabine, van Dalen, Thijs, Pathologie Groep Van Diest, Trialbureau Beeld, Cancer, Pathologie Stafondersteuning, Pathologie, Pathologie Pathologen staf, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Kanker, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, MS CGO, van Steenhoven, Julia E.C., Kuijer, Anne, van Diest, Paul J., van Gorp, Joost M., Straver, Marieke, Elias, Sjoerd G., Wesseling, Jelle, Rutgers, Emiel, Timmer-Bonte, Johanna N.H., Nieboer, Peter, Smilde, Tineke J., Imholz, Alex, Blanken, Charlotte F.J.M., Siesling, Sabine, and van Dalen, Thijs

Published
2018

50. Metformine: ondanks hoge leeftijd nog springlevend

Author

Brouwers, Koos, Nieboer, Peter, Wilffert, Berend, FarmacoTherapie, -Epidemiologie en -Economie, Methods in Medicines evaluation & Outcomes research, Reproductive Origins of Adult Health and Disease, and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Abstract

Nieuwe feiten maken dat de rol van metformine nog lang niet is uitgespeeld. Integendeel: door vele nieuwe toepassingen lijkt metformine inmiddels de status van ‘wondermiddel’ te krijgen. Binnen het geweld van dure innovaties is toepassing van en verder onderzoek naar oude en goedkope middelen zoals metformine een goede investering.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results